Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 14199
Label UNT Conférences

le (17m44s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.

How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.ISCP: Speaker: Felipe MARTINEZ, Cordoba, ARGCVCT: Speaker: Faiez ZANNAD, Nancy, FRAESC Working group in Pharmacology and Drug Therapy : Speaker: Christian TORP-PEDERSEN, Copenhagen, DENAbstract : L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 ESC Working group on cardiovascular pharmacology and drug therapyInternational Society of Cardiovascular Pharmacotherapy (ISCP)CardioVascular Clinical Trialists (CVCT)Joint sessionPERSONALIZED CARDIOVASCULAR MEDICINE AND DRUG DEVELOPMENT: TIME FOR A NEW TRIAL PARADIGMChairpersons: Juan Carlos KASKI, London, GBR ...
Voir la vidéo
Label UNT Conférences

le (36m52s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkersSpeaker: Stefan BLANKENBERG, Hamburg, GERAbstract : The role of biomarkersL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 ESC Working group on cardiovascular pharmacology and drug therapyInternational Society of Cardiovascular Pharmacotherapy (ISCP)CardioVascular Clinical Trialists (CVCT)Joint sessionPERSONALIZED CARDIOVASCULAR MEDICINE AND DRUG DEVELOPMENT: TIME FOR A NEW TRIAL PARADIGMChairpersons: Juan Carlos KASKI, London, GBR - Bertram PITT, Ann Arbor, USA - Luis RUILOPE, Madrid, ESP- “Drugs, in general, act not on ...
Voir la vidéo
Label UNT Conférences

le (16m37s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?Speaker: Jim JANUZZI, Boston, USADiscussant: James SNIDER, Critical Diagnostics, USAAbstract : How should Diagnostic and Prognostic Markers BeStudied? The measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach with which these potentially important tests have ...
Voir la vidéo
Label UNT Conférences

le (14m51s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel markerSpeaker: Stefan BLANKENBERG, Hamburg, GERDiscussant: Nancy GELLER, Bethesda, USAAbstract : Best statistical methods for evaluating the merits of a novel markerThe measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach ...
Voir la vidéo
Label UNT Conférences

le (17m30s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measuresSpeaker: Michael FELKER, Durham, USAAbstract : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measuresThe measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear ...
Voir la vidéo
Label UNT Conférences

le (14m45s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?Speaker: Felix MAHFOUD, Homburg, GERDiscussant: Michel AZIZI, Paris, FRAAbstract : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 HYPERTENSION TRIALIST WORKSHOP: AUTONOMIC MODULATION THERAPYChairpersons: George BAKRIS, Chicago, USA - Sverre E. KJELDSEN, Oslo, NORResistant hypertension is usually defined as uncontrolled hypertension despite the intake of at least 3 antihypertensive drugs in full doses ...
Voir la vidéo
Conférences

le (1h6m55s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: The value of omics and mendelian randomization studies (Daniel SWERDLOW)

MODIGLIANI Workshop 5 - Saturday December 1st, 2012THE ATHEROSCLEROSIS TRIALISTS FORUMChairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBRWebcast: Tabassome SIMON, Paris, FRAWill new compounds be able to reduce the residual risk in high risk patients when treatment targets based on new ESC guidelines have been achieved (e.g. LDL-C < 70mg/dl)?Despite widespread early intervention in acute coronary syndromes and complete revascularization of stenotic lesions complemented by aggressive polypharmacotherapy, still a high percentage of patients develop a secondary event.This has been shown in various registries and recent data from the GRACE registry have suggested that we grossly underestimate long-term risk ...
Voir la vidéo
Conférences

le (1h49m52s)

Semaine Médicale de Lorraine Nancy 2012 – Rencontre de médecine interne et de médecine générale

C0605Titre : Semaine Médicale de Lorraine Nancy 2012 – Rencontre de médecine interne et de médecine généraleCoordonnateur : Jean Dominique de KORWIN (Service de médecine D CHU de Nancy).Intervenant (e)(s) : Olivier BOUCHY (médecin généraliste Revigny) – Michel  MAIGNAN (service de médecine D CHU de Nancy) -  Paolo DI PATRIZIO (Médecine générale Faculté de Médecine de Nancy) - Claudia FARCAS TARALUNGA (médecine interne Hôpital de Toul).Résumé : Partir de cas concrets où l’analyse sémiologique clinique et des examens complémentaires rationnels permettent d’aboutir à un diagnostic dans des situations courantes mais complexes de médecine générale (anémie, syndrome inflammatoire...)L’auteur n’a pas transmis de conflit d’intérêt ...
Voir la vidéo
Conférences

le (25m33s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Endpoint related issues (Alexandre MEBAZAA)

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012:HEART FAILURE TRIALISTS WORKSHOPLEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALSChairpersons: Alexandre MEBAZAA, Paris, FRA - Christopher O’CONNOR, Durham, USAWebcast: Daniela DOBRE, Nancy, FRADecreasing the very high mortality and rate of re-hospitalization associated with acute worsening HF is one of the most important unmet needs in cardiovascular medicine. Despite positive signals in Phase II studies, no drug has proven to reduce the appallingly high mortality or readmission rates. The reasons for these ‘failed’ trials are multiple, including the adequacy of candidate drugs, dosing, patient selection and disease ...
Voir la vidéo

 
FMSH
 
Facebook Twitter Google+
Mon Compte